Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Breast Cancer
Lowering Dietary Fat Increases Long-Term Survival in Women with Hormone-Negative Breast Cancer
By
Alice Goodman
Breast Cancer
,
Solid Tumors
March 2015, Vol 6, No 2
San Antonio, TX—Results of a new nutrition study show that women who reduced their intake of dietary fat for 5 years after being diagnosed with early breast cancer had significantly lower rates of death from all causes compared with controls, at 15 years of follow-up; this reduction was seen specifically in women with hormone receptor (HR)-negative breast cancer. No long-term effect of dietary fat reduction on mortality was observed in women with HR-positive breast cancer. The results of the study, called Women’s Intervention Nutrition Study (WINS), were presented at the 2014 San Antonio Breast Cancer Symposium.
Read Article
Study Identifies Important Benefits of Cancer Survivorship Programs
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—Patients with breast cancer who attended survivorship clinics demonstrated improved compliance with follow-up visits, increased use of supportive services, and felt their concerns were better addressed, according to the results of a cancer center’s patient survey reported by Leah L. Dietrich, MD, an oncologist at Gundersen Health System, La Crosse, WI, at the 2014 Breast Cancer Symposium.
Read Article
Adding Luteinizing Hormone-Releasing Hormone Agonist to Chemotherapy Preserves Fertility in Women with Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—A second study adds to the body of evidence that including a luteinizing hormone-releasing hormone (LHRH) agonist with chemotherapy as treatment for breast cancer increases a younger woman’s likelihood of becoming pregnant.
Read Article
Most Preoperative Breast MRIs Requested by Nononcologists
By
Charles Bankhead
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—Preoperative breast magnetic resonance imaging (MRI) failed to influence clinical management in any subgroup of 257 patients with breast cancer, according to the results of a retrospective review that led one cancer center to discontinue the practice.
Read Article
HER2-Derived Vaccine Cuts Recurrences in Patients with High-Risk Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Solid Tumors
October 2014, Vol 5 , No 8
San Francisco, CA—A new GP2 peptide vaccine was safe and reduced the rate of breast cancer recurrence in women with high-risk breast cancer in a phase 2 clinical trial.
Read Article
Adjuvant Exemestane More Effective than Tamoxifen in Early-Stage Breast Cancer
By
Wayne Kuznar
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Chicago, IL—Adjuvant exemestane is more effective at preventing breast cancer recurrences than tamoxifen when given with ovarian function suppression (OFS) in young women with hormone receptor–positive early breast cancer, reported Olivia Pagani, MD, Clinical Director, Breast Unit, Oncology Institute of Southern Switzerland, Bellinzona, at the 2014 American Society of Clinical Oncology meeting.
Read Article
Guidelines Target Brain Metastases in HER2-Positive Breast Cancer
By
Eileen Koutnik-Fotopoulos
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
August 2014, Vol 5, No 6
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. Brain metastases are relatively common in patients with HER2-positive metastatic breast cancer, with up to 50% of patients developing metastases over time.
Read Article
ALTTO: Dual Anti-HER2 Adjuvant Therapy No Better than Trastuzumab Alone
By
Phoebe Starr
Breast Cancer
,
Personalized Medicine
,
Value-Based Care
August 2014, Vol 5, No 6
The addition of lapatinib (Tykerb) to trastuzumab (Herceptin) to create dual HER2 blockade was no better than trastuzumab alone in the adjuvant treatment of patients with HER2 breast cancer in the global phase 3 ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) trial, reported Martine J. Piccart-Gebhart, MD, PhD, Chair, Breast International Group, Brussels, Belgium, at a plenary session at the 2014 American Society of Clinical Oncology (ASCO) meeting.
Read Article
The Long Road to Rehabilitation: Sandra Wade’s Story on Surviving Breast Cancer
By
Julie K. Silver, MD
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
,
The Patient Perspective
August 2014, Vol 5, No 6
Sandra Wade first e-mailed me on July 15, 2011. As you can see in the excerpts from her correspondence with me below, she asked me to contact her oncologist and let her know that as a breast cancer survivor, Sandra had suffered more than she should have, because she was not referred for rehabilitation services.
Read Article
ASCO Guidelines Target Advanced HER2-Positive Breast Cancer
By
Eileen Koutnik-Fotopoulos
Breast Cancer
,
Personalized Medicine
,
Solid Tumors
June 2014, Vol 5, No 5
Approximately 15% to 20% of patients with breast cancer have HER2-positive disease. The American Society of Clinical Oncology (ASCO) released new clinical practice guidelines for the treatment of women with advanced HER2-positive breast cancer, focusing on systemic therapies.
Read Article
Page 9 of 13
4
5
6
7
8
9
10
11
12
13
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma